These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 15685669)

  • 41. Use of randomized controlled trials in organizational decision making: a cost-minimization approach.
    Cher DJ; Maclure M
    Am J Manag Care; 2000 Aug; 6(8):894-904. PubMed ID: 11186501
    [No Abstract]   [Full Text] [Related]  

  • 42. [Economical evaluation of drugs. A steering method for the pharmaceutical sector of the 1990's?].
    Grund J; Husbyn H
    Tidsskr Nor Laegeforen; 1994 Mar; 114(8):947-50. PubMed ID: 8191475
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The role of pharmacoeconomic guidelines for formulary approval: the Australian experience.
    Langley PC
    Clin Ther; 1993; 15(6):1154-76; discussion 1120. PubMed ID: 8111812
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Reference Pricing in Germany: Implications for U.S. Pharmaceutical Purchasing.
    Robinson JC; Panteli D; Ex P
    Issue Brief (Commonw Fund); 2019 Feb; 2019():1-8. PubMed ID: 30883061
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The promise of pharmacogenetics: assessing the prospects for disease and patient stratification.
    Smart A; Martin P
    Stud Hist Philos Biol Biomed Sci; 2006 Sep; 37(3):583-601. PubMed ID: 16980196
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Arbitration Board Setting Reimbursement Amounts for Pharmaceutical Innovations in Germany When Price Negations between Payers and Manufacturers Fail: An Empirical Analysis of 5 Years' Experience.
    Ludwig S; Dintsios CM
    Value Health; 2016 Dec; 19(8):1016-1025. PubMed ID: 27987628
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacy benefit management: the right Rx?
    Etheredge L
    Res Agenda Brief; 1995 Apr; (1):1-11. PubMed ID: 12856664
    [No Abstract]   [Full Text] [Related]  

  • 48. [The budget control function of the Drug Reimbursement System].
    Pronk MH; Bonsel GJ; van der Kuy A
    Ned Tijdschr Geneeskd; 2002 Sep; 146(37):1729-33. PubMed ID: 12357873
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The strategic interaction between firms and formulary committees: effects on the prices of new drugs.
    García-Alonso MD; García-Mariñoso B
    J Health Econ; 2008 Mar; 27(2):377-404. PubMed ID: 18276026
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Budget impact analysis: review of the state of the art.
    Mauskopf JA; Earnshaw S; Mullins CD
    Expert Rev Pharmacoecon Outcomes Res; 2005 Feb; 5(1):65-79. PubMed ID: 19807561
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Weighing the evidence: trends in managed care formulary decision making.
    de Lissovoy G
    J Clin Psychiatry; 2003; 64 Suppl 17():29-32. PubMed ID: 14680425
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Twenty years of using economic evaluations for drug reimbursement decisions: what has been achieved?
    Drummond M
    J Health Polit Policy Law; 2013 Dec; 38(6):1081-102. PubMed ID: 23974475
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cost-effectiveness analysis: from science to application.
    Berger ML; Teutsch S
    Med Care; 2005 Jul; 43(7 Suppl):49-53. PubMed ID: 16056009
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Using pharmacoeconomic analysis to make drug insurance coverage decisions.
    Anis AH; Rahman T; Schechter MT
    Pharmacoeconomics; 1998 Jan; 13(1 Pt 2):119-26. PubMed ID: 10176146
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmaceutical expenditure, total health-care expenditure and GDP.
    Clemente J; Marcuello C; Montañés A
    Health Econ; 2008 Oct; 17(10):1187-206. PubMed ID: 18050150
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Your next move in managing drug costs.
    Heenan J
    Bus Health; 1995 Aug; 13(8):31-2, 36, 38. PubMed ID: 10153416
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Similarities and differences between five European drug reimbursement systems.
    Franken M; le Polain M; Cleemput I; Koopmanschap M
    Int J Technol Assess Health Care; 2012 Oct; 28(4):349-57. PubMed ID: 22989410
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Falling into the doughnut hole: drug spending among beneficiaries with end-stage renal disease under Medicare Part D plans.
    Patel UD; Davis MM
    J Am Soc Nephrol; 2006 Sep; 17(9):2546-53. PubMed ID: 16855016
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evidence-based decision-making within Australia's pharmaceutical benefits scheme.
    Lopert R
    Issue Brief (Commonw Fund); 2009 Jul; 60():1-13. PubMed ID: 19639714
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The impact of two pharmaceutical risk-sharing agreements on pricing, promotion, and net health benefits.
    Zaric GS; Xie B
    Value Health; 2009; 12(5):838-45. PubMed ID: 19490563
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.